all the information, none of the junk | biotech • healthcare • life sciences

MDRNA Sells Osteoporosis Drug

Xconomy Seattle — 

MDRNA, the Bothell, WA-based developer of drugs using RNA interference technology, said today it has sold its assets related to a nasal spray drug for osteoporosis to Par Pharmaceutical. MDRNA (NASDAQ: MRNA) will receive an undisclosed upfront cash payment, and a double-digit percentage royalty on sales of the product, a generic form of calcitonin-salmon nasal spray. MDRNA has been running low on cash, and it noted that Par will assume manufacturing and operating costs related to the drug.

By posting a comment, you agree to our terms and conditions.